Indications
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP?NETs) in adults.
Composition
- Active substance
- lutetium (177Lu) oxodotreotide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lutathera
- Active substance
- lutetium (177Lu) oxodotreotide
- ATC code
- V10XX04
- Group
- Various
- Therapeutic area
- Neuroendocrine Tumors
- Marketing authorisation holder
- Advanced Accelerator Applications
- Status
- Authorised